More than 1,000 people have had their entire genetic make-up decoded as part of a long-term study to gain insight into why some people’s brains age better than others. Scientists in Edinburgh have sequenced the DNA of more than 1,300 people taking part in a decades-long study into ageing and memory. The development will enable [...]
Using aspirin urgently could substantially reduce the risk of major strokes in patients who have minor ‘warning’ events, a group of European researchers has found. Writing in The Lancet, the team say that immediate self-treatment when patients experience stroke-like symptoms would considerably reduce the risk of major stroke over the next few days. Aspirin is already [...]
BIAL has announced that the European Medicines Agency (EMA) has accepted Bial’s application to review recent clinical trial data for Zebinix(R) (eslicarbazepine acetate) for its use as a once-daily monotherapy in the treatment of adult patients with newly-diagnosed partial-onset (focal) epilepsy. Partial-onset seizures, also known as focal, are the most common type and are therefore [...]
ImmunoCellular Therapeutics Ltd has announced that the company has received approval from regulatory authorities in Canada, the UK, and the Netherlands to initiate the ICT-107 Phase 3 registration trial in patients with newly-diagnosed glioblastoma. Patient screening is anticipated to commence shortly and the first clinical supplies could be manufactured for qualifying patients in Canada and [...]
An international public-private consortium of researchers brought together by the University of Dundee and led by The Michael J. Fox Foundation for Parkinson’s Research has identified and validated for the first time the cellular role of a primary Parkinson’s disease drug target. In work published in eLife, the team comprising investigators from the University of Dundee, Max [...]
An epilepsy drug could lead to a new treatment that protects nerve damage in MS patients, according to research published in the Lancet Neurology. Researchers, led by Dr Raj Kapoor from the UCL Institute of Neurology, found the anti-convulsant drug phenytoin protected neural tissue in patients with optic neuritis. Optic neuritis is a symptom of MS [...]
Eisai and Charles River Laboratories have announced that they have signed a collaboration agreement which will see Charles River scientists work at Eisai's research and development facilities in Hatfield, UK. The collaboration will involve Charles River supporting Eisai scientists from Japan, USA and the UK on a range of synthetic and medicinal chemistry projects, including those seeking novel treatments for neurological diseases. [...]
